Acuitas Therapeutics

Verve Therapeutics, Inc. has paused enrollment in its Phase Ib Heart-1 trial of gene-edited cholesterol medicine VERVE-101 after a patient experienced liver enzyme elevations and low platelet counts.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Antibiotics Firm Agrees To Go Private F

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. PhoreMost To Deploy SITESEEKER Platform

The molecules that deliver work orders to cellular protein factories may have been discovered in 1961, but it was not until they were harnessed over 60 years later to protect billions of people from a